Rogaratinib

DRUG3 trials

Sponsors

Swiss Cancer Institute, Dana-Farber Cancer Institute, National Cancer Institute (NCI)

Conditions

Bladder CancerLocally Advanced Gastrointestinal Stromal TumorLocally Advanced SarcomaMetastatic Gastrointestinal Stromal TumorMetastatic SarcomaSquamous-cell Non-small Cell Lung CancerStage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8

Phase 2

Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)

TerminatedNCT03762122

Swiss Cancer InstituteSquamous-cell Non-small Cell Lung Cancer

Start: 2019-07-25End: 2021-08-24Updated: 2022-11-09

Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression

WithdrawnNCT04040725

Dana-Farber Cancer InstituteBladder Cancer

Start: 2019-11-27End: 2019-11-27Updated: 2019-12-17

Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)

Active, not recruitingNCT04595747

National Cancer Institute (NCI)Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma, Metastatic Gastrointestinal Stromal Tumor +5

Start: 2021-05-03End: 2027-07-31Target: 48Updated: 2026-07-31

Related Papers

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial

Nature Medicine2026-05-26

Abstract CT215: Fibroblast growth factor receptor (FGFR) inhibition demonstrates anti-tumor activity in succinate dehydrogenase deficient gastrointestinal stromal tumor (SDHd GIST)

Cancer Research2025-04-251 citations

Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.

Journal of Clinical Oncology2021-05-204 citations

Early clinical experience with the pan-FGFR inhibitor rogaratinib in patients with non-small cell lung cancer selected based on FGFR mRNA expression levels.

Journal of Clinical Oncology2019-05-206 citations